Combination of Two Cancer Drugs May Work Against Alzheimer’s

Scientists at Gladstone Institutes and UC San Francisco (UCSF) have identified cancer drugs that show promise for reversing the changes that occur in the brain during Alzheimer’s disease, potentially slowing or even reversing its symptoms.

The study, published in Cell, first analyzed how Alzheimer’s altered gene expression (the activity of genes in a cell), in single cells in the human brain. Then, researchers looked for existing drugs that were already approved by the US Food and Drug Administration (FDA) and cause the opposite changes to gene expression.

They were looking specifically for drugs that would reverse the gene expression changes in neurons and in other types of brain cells called glia, all of which are damaged or altered in Alzheimer’s disease. Next, the researchers analyzed millions of electronic medical records to show that patients who took some of these drugs as part of their treatment for other conditions were less likely to get Alzheimer’s disease.

When they tested a combination of the two top drugs—both of which are cancer medications—in a mouse model of Alzheimer’s, it reduced brain degeneration in the mice, and even restored their ability to remember.

“Alzheimer’s disease comes with complex changes to the brain, which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly,” says Marina Sirota, PhD, the interim director of the UCSF Bakar Computational Health Sciences Institute, professor of pediatrics, and co-senior author of the paper. “We’re excited that our computational approach led us to a potential combination therapy for Alzheimer’s based on existing FDA-approved medications.”

Big Data From Patients and Cells Points to a New Alzheimer’s Therapy

Alzheimer’s disease affects 7 million people in the U.S. and causes a relentless decline in cognition, learning, and memory. Yet decades of research have only produced two FDA-approved drugs, neither of which can meaningfully slow the decline. 

“Alzheimer’s is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,” says Yadong Huang, MD, PhD, senior investigator and director of the Center for Translational Advancement at Gladstone, professor of neurology and pathology at UCSF, and co-senior author of the paper. “This makes it very challenging for drug development—which traditionally produces one drug for a single gene or protein that drives disease.”

The team took publicly available data from three studies of the Alzheimer’s brain that measured single-cell gene expression in brain cells from deceased donors with or without Alzheimer’s disease. They used this data to produce gene expression signatures for Alzheimer’s disease in neurons and glia.

The researchers compared these signatures with those found in the Connectivity Map, a database of results from testing the effects of thousands of drugs on gene expression in human cells. Out of 1,300 drugs, 86 reversed the Alzheimer’s disease gene expression signature in one cell type, and 25 reversed the signature in several cell types in the brain. But just 10 had already been approved by the FDA for use in humans. 

Poring through records housed in the UC Health Data Warehouse, which includes anonymized health information on 1.4 million people over the age of 65, the group found that several of these drugs seemed to have reduced the risk of developing Alzheimer’s disease over time.

“Thanks to all these existing data sources, we went from 1,300 drugs, to 86, to 10, to just five,” says Yaqiao Li, PhD, a postdoctoral scholar in Huang’s lab at Gladstone and former graduate student in Sirota’s UCSF lab, who is first author of the paper. “In particular, the rich data collected by all the UC health centers pointed us straight to the most promising drugs. It’s kind of like a mock clinical trial.”

A Combination Therapy Poised for Primetime

Li, Huang, and Sirota chose two cancer drugs out of the top five drug candidates for laboratory testing. They predicted one drug, letrozole, would remedy Alzheimer’s in neurons; and another, irinotecan, would help glia. Letrozole is usually used to treat breast cancer; irinotecan is usually used to treat colon and lung cancer.

The team used a mouse model of aggressive Alzheimer’s disease with multiple disease-related mutations. As the mice aged, symptoms resembling Alzheimer’s emerged, and they were treated with one or both drugs.

“It’s so exciting to see the validation of the computational data in a widely used Alzheimer’s mouse model.”

Yadong Huang, MD, PhD

The combination of the two cancer drugs reversed multiple aspects of Alzheimer’s in the animal model. It undid the gene expression signatures in neurons and glia that had emerged as the disease progressed, and reduced the formation of toxic clumps of proteins and brain degeneration. And, importantly, it restored memory.

“It’s so exciting to see the validation of the computational data in a widely used Alzheimer’s mouse model,” Huang says. He expects the research to advance soon to a clinical trial so the team can directly test the combination therapy in Alzheimer’s patients.

“If completely independent data sources, such as single-cell expression data and clinical records, guide us to the same pathways and the same drugs, and then resolve Alzheimer’s in a genetic model, then maybe we’re onto something,” Sirota says. “We’re hopeful this can be swiftly translated into a real solution for millions of patients with Alzheimer’s.”